Once-daily deferasirox dispersible tablets (DT) have a well-defined safety and efficacy profile and, compared with parenteral deferoxamine, provide greater patient adherence, satisfaction, and quality of life. However, barriers still exist to optimal adherence, including gastrointestinal tolerability and palatability, leading to development of a new film-coated tablet (FCT) formulation that can be swallowed with a light meal, without the need to disperse into a suspension prior to consumption.
, providing greater compliance, patient satisfaction, and health-related quality of life. 7, 8 The efficacy and safety of deferasirox DT has been well-defined through an extensive clinical trial program in adult and pediatric patients with a variety of anemias, including thalassemia, myelodysplastic syndromes (MDS), sickle-cell disease, and other rare anemias, [9] [10] [11] [12] [13] and has been used in clinical practice worldwide for over a decade. Nonetheless, barriers to optimal patient acceptance of treatment still exist with deferasirox DT, including palatability, the need to take the drug in a fasting state (ie, not being able to take with food), and drug-related side effects, notably gastrointestinal (GI) tolerability. 14 Both deferasirox FCT and DT are once-daily, oral iron chelators that are dosed based on body weight. The FCT contains the same active substance, dose-adjusted to achieve comparable exposure to that achieved with the DT, 15 but excipients (lactose and sodium lauryl sulfate) have been removed. As a result of increased bioavailability of the FCT, doses required to achieve the same chelation effect are 30%
lower than the DT. 15 Deferasirox DT is taken according to labeling recommendations on an empty stomach, at least 30 min before the next meal, and administration requires careful dispersion of the tablets in a glass of water, orange juice, or apple juice, and has a chalky consistency.
Deferasirox FCT can be taken orally on an empty stomach or with a light meal (<7% fat content and 250 calories), offering a simpler and more convenient mode of administration, and potentially improved GI tolerability (due to a change in excipients and administration with food).
The phase II, randomized, open-label ECLIPSE study primarily evaluated the overall safety profile, as well as pharmacokinetics (PK), and patient-reported outcomes (PROs) of deferasirox FCT and DT formulations in patients aged 10 years with transfusion-dependent thalassemia (TDT) or very-low-, low-, or intermediate-risk MDS, requiring iron chelation therapy.
| M E T H O D S

| Key inclusion/exclusion criteria
Male and female patients aged 10 years with TDT or revised International Prognostic Scoring System (IPSS-R) very-low-, low-, or intermediate-risk MDS were enrolled; patients could have been previously treated with iron chelators and required treatment with deferasirox DT doses 30 mg/kg/day (TDT) or 20 mg/kg/day (MDS) or be chelation-naïve. Patients were also required to have a transfusion history of 20 packed red blood cell units, anticipated transfusion requirements of 8 units/year during the study, and serum ferritin >1000 ng/mL at screening. Key exclusion criteria were: creatinine clearance (CrCl) below contraindication limit as per local label (<60 mL/min or <40 mL/min); serum creatinine (SCr) >1.5 3 upper limit of normal (ULN); alanine aminotransferase (ALT) >5 3 ULN (unless liver iron concentration confirmed as >10 mg Fe/g dry weight 6 months prior to screening); urine protein/creatinine ratio (UPCR) >0.5 mg/mg; or impaired GI function.
| Study design
ECLIPSE was an open-label, randomized, multicenter, two-arm, phase II study with the primary endpoint after 24 weeks of treatment (Supporting Information Figure S1 ). Randomization was stratified by underlying disease and previous chelation treatment. In all chelation-naïve patients, the starting deferasirox dose was 20 mg/kg/day with DT or 14 mg/kg/day with FCT. For previously treated patients, a washout period of 5 days was required before randomization; all pre-treated patients well managed on treatment with deferasirox DT, deferoxamine or deferiprone were requested to start on a DT or FCT dose equivalent to their pre-washout dose (eg, 20 mg/kg/day DT equivalent to 14 mg/ kg/day FCT equivalent to 75 mg/kg/day deferiprone equivalent to 40 mg/kg/day deferoxamine). Deferasirox DT was taken on an empty stomach, at least 30 min before the next meal; FCT was taken (no later than 12:00 pm) with or after a light meal. Dose adjustments to improve treatment response based on serum ferritin levels and investigator's judgment were recommended every 4 weeks for chelation-naïve patients and every 3 months for pre-treated patients, in increments of 5-10 mg/kg/day for DT or 3.5-7 mg/kg/day for FCT, up to a maximum dose of 40 mg/kg/day for DT and 28 mg/kg/day for FCT. Dose adjustments based on safety and dose reductions for patients unable to tolerate the protocol-specified dosing schedule were allowed at any time during the study.
The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki, and was approved by independent ethics committees at participating sites. Patients (or parents/ guardians) provided written, informed consent prior to enrollment.
| Outcomes
The primary endpoint was overall safety of deferasirox FCT and deferasirox DT formulations, measured by frequency and severity of adverse events (AEs) and changes in laboratory values from baseline to 24 weeks. Secondary endpoints included the evaluation of both formulations on selected GI AEs (diarrhea, constipation, nausea, vomiting, and abdominal pain) during treatment, estimation of treatment compliance, evaluation of both formulations on patient satisfaction, palatability, and GI symptoms using PROs and evaluation of the PK of both formulations.
Safety was evaluated by monitoring and assessing AEs, changes in laboratory parameters, and clinical observations from the start of study treatment to 30 days after the last intake of study drug. Compliance to treatment was evaluated by relative consumed tablet count (total consumed tablet count/total prescribed tablet count) and patient-reported treatment compliance using a daily compliance questionnaire. Patient satisfaction, palatability of medicine, and GI symptoms were measured for both formulations using PRO questionnaires (modified Satisfaction 
| Statistical evaluations
Standard descriptive analyses were performed for both formulation groups. No hypothesis was tested. The incidence of any AEs overall and by severity was summarized by treatment using frequency counts, percentages of patients, and 95% confidence intervals (CIs) for percentages obtained using Clopper-Pearson method. Laboratory data were summarized using absolute change from baseline by treatment arm at each post-baseline time window. The safety analysis set included all patients who received at least one dose of the study drug and was used for all safety evaluations. The PK analysis set consisted of all patients who received at least one dose of study medication and had at least one evaluable concentration measurement and was used for all PK analyses. Serum ferritin data were considered as an exploratory, non-safety outcome; absolute and relative change from baseline were summarized by treatment arm at each post-baseline visit.
| R E S U LTS
In total, 173 patients were randomized 1:1 to DT (n 5 86) or FCT (n 5 87; weeks of treatment; patients discontinued treatment because of AEs (n 5 10), protocol deviation (n 5 5), withdrawal of consent (n 5 3), patient guardian decision (n 5 2), and other reasons (administrative problems, death, and physician's decision, n 5 1 each).
| Exposure to treatment and compliance
The mean actual deferasirox DT dose 6 SD received during the 24-week study was 27.5 6 7.73 mg/kg/day over a mean duration of 154.5 6 44.67 days (median 168.0 days); the mean actual deferasirox FCT dose 6 SD received was 20.8 6 5.44 mg/kg/day over a mean duration of 163.2 6 27.76 days (median 169.0 days; Table 2 ). More patients receiving FCT were in the longest exposure category (12 weeks; DT 89.5%; FCT 96.6%) and highest mean actual dose category (35 mg/kg/day DT/24.5 mg/kg/day FCT; DT n 5 16, 18.6%; FCT n 5 27, 31.0%; Table 2 ). However, post-hoc analyses identified that 23 patients on FCT (26%) were started on a dose that was higher than recommended in the protocol compared with eight patients (9.3%) on DT (not recognized or reported by the investigators as dosing error).
Over 24 weeks, dose was interrupted at least once in 43 patients 3.2 | Safety of deferasirox DT and FCT
| Adverse events
Investigator-reported AEs regardless of relationship to deferasirox were reported in 77 patients (89.5%) on DT and 78 patients (89.7%) on FCT ( Table 3 ). The most frequently reported AEs were diarrhea, nausea, and abdominal pain ( Six patients in the deferasirox DT arm (7.0%) and five patients in the deferasirox FCT arm (5.7%) had one or more AEs where study drug was discontinued. GI-related disorders were the most common reason for study drug discontinuation in patients receiving DT (n 5 4 [4.7%];
abdominal pain, abdominal pain upper, diarrhea, dysphagia), whereas only one patient receiving FCT discontinued treatment because of a GI event (Crohn's disease).
| Laboratory parameters
Mean SCr increased initially but stabilized during the study, remained within the normal range, and was similar with both formulations. In most patients with normal values at baseline, SCr remained below ULN during the study (DT 85.9% and FCT 90.8%); two consecutive SCr values >ULN and >33% increase from baseline were reported in four and three patients in the DT and FCT groups, respectively. CrCl remained greater than 60 mL/min during the study for most patients (DT 87.8%
and FCT 91.9%). Of 11 patients receiving DT and eight receiving FCT who experienced at least one CrCl value <60 mL/min during the study, four patients and one patient, respectively, had values below this threshold at baseline. The proportions of patients with post-baseline laboratory parameters meeting the specified criteria for notable values were similar for both formulations (Supporting Information Table S1 ).
| Post-hoc evaluation of patients with renal events (renal adverse events and abnormal renal laboratory parameters)
For the purpose of this detailed evaluation of patients with renal AEs and abnormal renal laboratory parameters, a patient was classified as experiencing a renal event if one of the following criteria was met: a reported AE with the following preferred terms: renal impairment, blood creatinine increased, blood creatinine abnormal, glomerular filtration rate decreased, UPCR increased, proteinuria, UPCR abnormal, urine albumin/creatinine ratio increased; SCr >33% above baseline and >ULN in two consecutive values at least 7 days apart; recalculated CrCl <40 mL/min; two consecutive UPCR values >0.5 mg/mg at least 48 hours apart. Fifty-nine patients met one or more of these criteria:
26 patients receiving DT and 33 patients receiving FCT. Evaluation of the starting dose against the study protocol-recommended dose range revealed that more patients receiving FCT were started on doses above the protocol-recommended range (n 5 23; 26.4%) than patients receiving DT (n 5 8; 9.3%; 
mmol/L).
PK variability shown as coefficient of variation of geometric mean was smaller with FCT than DT. Results were similar with or without dose normalization, which suggest that overall exposure to deferasirox was similar for both formulations, with slightly higher post-dose concentrations with FCT. PK results observed in this study were consistent with data previously obtained in healthy volunteers (data on file).
| Patient-reported outcomes
Completion rates for PRO instruments were: 80% for the PRO questionnaire at the beginning of the study, reducing to 70% by month 24; 60% reducing to 30% for the compliance diary; and 70% reducing to 35% for the GI symptom diary. Throughout the 24-week study period, for modified SICT, patients receiving FCT reported consistently greater adherence (attributable to: finding it easier to remember to take medication, thinking less often about stopping medication, following instructions from the doctor more closely, finding medication easier to take, being less bothered by the time taken to prepare medication and the waiting time before eating), greater satisfaction/preference (in general and also with administration of medicine), and consistently fewer concerns (attributable to: being less worried about not swallowing enough medication, experiencing fewer limitations in daily activities, feeling less concerned about side effects) than patients receiving DT ( Figure 1A-C) . The difference in score between the two formulations was >1 point (minimal important difference
[MID]) for all three domains at every visit, and no overlapping CIs at almost every timepoint, indicating a clinically meaningful difference between formulations. Patients receiving FCT reported consistently higher satisfaction on palatability scores, reporting no taste or aftertaste and that they were able to swallow the full amount of medicine with the right amount of liquid compared with patients receiving DT ( Figure 1D ). The overall GI symptom scores were low for both formulations, indicating patients experienced very little trouble/concern associated with GI symptoms ( Figure 1E ). Results favored FCT with patients reporting near-perfect scores for all three modified SICT domains and palatability.
| DISCUSSION
The ECLIPSE study evaluated safety, PK, and PRO of the original deferasirox DT formulation and the new dose-adjusted FCT formulation, which contains the same active substance and can be swallowed without the need to disperse into a suspension, in patients with lower-risk Although the study was only 6 months, a reduction in serum ferritin of 14% and 4.1% was observed with FCT and DT, respectively. In addition to greater compliance with treatment, it was found that a larger proportion of patients in the FCT group received a higher than recommended dose, which could have contributed to the observed serum ferritin reduction. Further analyses are warranted to specifically determine the effects of deferasirox FCT on the serum ferritin levels.
The PRO analyses, using instruments validated within this trial,
show a benefit in favor of deferasirox FCT in all domains for the modified SICT, including greater adherence, greater satisfaction, fewer concerns, and better palatability with respect to taste and ability to consume medicine; patients receiving FCT achieved clinically meaningful and important differences compared with patients receiving DT for all domains. Overall, all patients were satisfied with their medicine during the study period; satisfaction scores were higher with deferasirox FCT compared with DT at all visits.
GI disturbances are often reported during clinical evaluation of deferasirox, usually mild-to-moderate and occurring early in the course of treatment. 16 As deferasirox FCT can be taken with a light meal and also lacks the excipients lactose and sodium lauryl sulfate, both found in the original DT formulation and possibly implicated in GI AEs, it was expected that deferasirox FCT would show improved GI tolerability.
Although similar numbers of patients in each arm experienced one or more GI AEs or received dose adjustments as a result of GI AEs, 12.8% and 4.6% of patients in the deferasirox DT and FCT groups, respectively, experienced severe GI AEs (including diarrhea, nausea, and abdominal pain) and four patients (DT) and one patient (FCT) discontinued treatment because of GI AEs. These results were reflected in the PROs: patients receiving FCT reported little or no concern with GI symptoms. Taken together, these results suggest that the GI tolerability profile may be improved with FCT compared with DT, which could be because of the change in excipients and/or the ability to take the medicine with a light meal. Further insight should be gained once longer-term data are available.
In the current study, more patients receiving FCT experienced renal AEs or abnormal renal parameters than those receiving DT, although the number of patients with renal laboratory values in the notable/extended ranges were either similar or lower in the FCT arm.
Renal laboratory changes and AEs are well characterized with deferasirox therapy and are generally mild, non-progressive, and reversible. 17 As such, the observed imbalance in reported renal events between the two treatment arms are likely attributed to a larger proportion of patients in the FCT group receiving a higher than recommended dose, as well as non-adherence to protocol-recommended dose modifications and (renal) exclusion criteria during the relatively short duration of the study. Longer-term follow-up of patients is warranted to confirm whether the FCT has any notable effect on the occurrence of renal events.
This study demonstrates that to achieve optimal treatment benefits from iron chelation with deferasirox, it is highly recommended to manage and monitor patients in accordance with the product label. In particular, the results highlight the importance of ensuring that patients start treatment on the correct dose. Care should be taken when switching patients to FCT to ensure a dose equivalent to their previous iron chelation treatment is administered (eg, FCT doses are 30% lower than DT doses, conversion factor 1.43). Evaluation of PK data in this study confirmed that patients treated with dose-adjusted FCT achieved comparable exposure to that achieved with DT, with similar pre-dose deferasirox levels and slightly higher 2-h post-dose levels observed with FCT.
Patient survival can be affected by compliance with medical treatment, particularly iron chelation, which in turn can be influenced by a number of factors, including patient satisfaction with/preference for their medication. 3, 18 Patient satisfaction rates for deferasirox DT have been reported to be as high as 90%, 19 yet studies have shown that most patients dislike the mode of administration for deferasirox DT and would prefer to be able to take their medication with food. 20 Barriers such as these likely contribute to a reduced patient-reported adherence to deferasirox DT of 67-86%. 21 To improve patient satisfaction and palatability of medication, and thereby adherence, the new FCT was developed to be taken with or after a light meal and was manufactured without sodium lauryl sul- 
